Nominees for Absolute Worst Bio-Technology CEOs of 2014 Are ...
at The Street - Mon Dec 15, 10:49AM CST
The CEOs of Aegerion, Dendron, CytRx, Galena, Repros, Northwest Bio and Retrophin deserve jeers for their performances this year, but who's the worst of the bunch?
NWBO: 5.58 (+0.04), DNDN: 0.13 (-0.02), RTRX: 12.92 (+0.19), CYTR: 2.58 (+0.03), RPRX: 8.88 (+0.24), GALE: 1.49 (-0.02), AEGR: 21.59 (-0.27)
This Illegal Drug Could Be the Answer to Fighting Brain Cancer
Sean Williams, The Motley Fool - Motley Fool - Sun Dec 14, 10:41AM CST
Source: National Cancer Institute via Wikimedia Commons. There's pretty much nothing scarier than being told you have cancer. Although I've personally never been given this dreaded diagnosis, I was there by my mother's side when she was told in...
NWBO: 5.58 (+0.04)
NW BIO RECAPS 2014 PROGRESS, PROVIDES DCVAX-DIRECT TRIAL UPDATE AT OPPENHEIMER'S 25TH ANNUAL HEALTHCARE CONFERENCE
PR Newswire - Thu Dec 11, 10:59AM CST
Northwest Biotherapeutics (NASDAQ: NWBO) ("NW Bio"
NWBO: 5.58 (+0.04)
Northwest Biotherapeutics: An Analysis Of What We Know About DCVax Direct
Smith On Stocks - at Seeking Alpha - Mon Dec 01, 5:23AM CST
NWBO: 5.58 (+0.04), KITE: 51.96 (+0.45)
Commit To Buy Northwest Biotherapeutics At $3, Earn 25% Using Options
StockOptionsChannel.com - Wed Nov 26, 10:34AM CST
Investors considering a purchase of Northwest Biotherapeutics Inc stock, but cautious about paying the going market price of $5.16/share, might benefit from considering selling puts among the alternative strategies at their disposal. One...
NWBO: 5.58 (+0.04)
Northwest Biotherapeutics' DCVax-L: A Reimbursement Perspective
Ryan Pawell - at Seeking Alpha - Sun Nov 23, 3:41AM CST
NWBO: 5.58 (+0.04), DNDN: 0.13 (-0.02)
Update: Northwest Bio Benefits From Two Financings, Woodford Makes Encouraging Investment
Trevor Lowenthal - at Seeking Alpha - Fri Nov 21, 7:16AM CST
NWBO: 5.58 (+0.04)
Biotech Stock Mailbag: Northwest Bio, Celldex, Puma, MannKind
at The Street - Fri Nov 21, 5:00AM CST
Biotech columnist Adam Feuerstein answers readers' questions about health care.
NWBO: 5.58 (+0.04), CLDX: 17.08 (-0.18), MNKD: 5.68 (+0.18), PBYI: 189.96 (+0.12)
Northwest Biotherapeutics posts 3Q loss
Automated Insights - Thu Nov 20, 5:51PM CST
BETHESDA, Md. (AP) _ Northwest Biotherapeutics Inc. (NWBO) on Thursday reported a loss of $21 million in its third quarter.
NWBO: 5.58 (+0.04)
Northwest Biotherapeutics: Capital Raise Of $35 Million Could Be A Positive Catalyst For The Stock
Smith On Stocks - Seeking Alpha - Thu Nov 20, 10:21AM CST
$35 Million Capital Raise Strengthens Balance Sheet Northwest Biotherapeutics (NASDAQ: NWBO ) announced after the market close on November 19th that it had completed a deal with the United Kingdom money manager Woodford Equity Income Fund to raise...
NWBO: 5.58 (+0.04)
NW BIO ANNOUNCES FINANCINGS TOTALING $35 MILLION TO EXPAND AND ACCELERATE DCVAX®-L AND DCVAX®-DIRECT PROGRAMS
PR Newswire - Wed Nov 19, 2:20PM CST
Northwest Biotherapeutics (NASDAQ: NWBO) ("NW Bio"
NWBO: 5.58 (+0.04)
Celldex Therapeutics To Enter Talks With FDA
Steven Giardino - Seeking Alpha - Tue Nov 18, 9:26AM CST
On Friday, Celldex Therapeutics (NASDAQ: CLDX ) announced results from a recently near completed Ph II trial testing Rindopepimut in recurrent glioblastoma ((rGBM)). The 72 patient, randomized, placebo controlled study (gold standard of trial design)...
NWBO: 5.58 (+0.04), CLDX: 17.08 (-0.18), SRPT: 13.88 (+0.47)
Product and Pipeline Analysis of the Global Vaccines Market
M2 - Tue Nov 11, 10:32AM CST
Research and Markets (http://www.researchandmarkets.com/research/4nt5s9/product_and) has announced the addition of the "Product and Pipeline Analysis of the Global Vaccines Market " report to their offering. Vaccines represent a class of biologics that are administered to prevent infectious diseases to reduce mortality and morbidity. It is estimated that the introduction of vaccines has reduced the incidence of various diseases by greater than 90%. This study examines the global vaccines market, including marketed products and products under clinical development. It also presents an overview of the value chain and regulatory environment, and offers profiles of key marketed and pipeline products. The market is segmented into infectious disease vaccines, cancer vaccines, allergy vaccines, and others (e.g., vaccines for physiological disorders such as diabetes and Alzheimer's disease). The base year is 2013. Key Findings:Vaccines are a class of biologics administered to prevent infectious diseases and reduce mortality and morbidity. - Vaccines are now available for prevention of about infectious diseases. - Coupled with powerful techniques such as polymerase chain reaction (PCR), mass spectrometry, and next-generation sequencing, the vaccine industry experienced a paradigm shift resulting in innovation and engineering of novel vaccines such as dendritic cell, DNA, and synthetic. - Infectious disease vaccines-particularly viral vaccines-represent the largest share in terms of products under clinical trial. There is an increased focus on developing vaccines with alternative delivery routes, such as oral and intranasal, to effectively replace the conventional injection method of administration. - One of the hallmarks of vaccine development is the improved understanding of the immune system. As a result, developers are pursuing vaccines for physiological diseases. - Developers also are researching vaccines for emerging infectious diseases such as respiratory syncytial virus (RSV), norovirus, human immunodeficiency virus (HIV), Epstein-Barr, malaria, and Leishmaniasis. - The United States, Europe, and Japan represent the largest markets for vaccine manufacturers; however, with increasing healthcare spending and awareness, emerging regions represent the fastest-growing and attractive markets. Key Topics Covered: 1. Executive Summary 2. Methodology and Scope 3. Introduction 4. Global Regulatory Oversight 5. Competitive Landscape 6. Competitive Landscape-Bacterial Vaccines 7. Competitive Landscape-Viral Vaccines 8. Competitive Landscape-Parasitic Vaccines 9. Competitive Landscape-Cancer Vaccines 10. Competitive Landscape-Allergy Vaccines 11. Competitive Landscape-Other Vaccines 12. Bacterial Vaccine Product Dashboard 13. Viral Vaccine Product Dashboard 14. Parasitic Vaccine Product Dashboard 15. Cancer Vaccine Product Dashboard 16. Allergy Vaccine Product Dashboard 17. Other Vaccine Products Dashboard 18. Timeline of Key Events 19. Conclusions Companies Mentioned - AFFiRiS - Archivel Farma - Biondvax - Bionor Pharma - Dendreon - GSK - Greer Laboratories - Immunitor - Inovio - Merck & Co - Nabi - Northwest Biotherapeutics - Novartis - PaxVax - Pfizer - Sanofi - Vaccinogen For more information visit http://www.researchandmarkets.com/research/4n...roduct_and
NWBO: 5.58 (+0.04), MRK: 57.46 (+0.25), NVS: 93.91 (+0.66)
NW BIO MAKING A JOINT POSTER PRESENTATION ON ITS DCVAX-DIRECT TRIAL AT THE 29TH ANNUAL SITC MEETING
PR Newswire - Fri Nov 07, 8:15AM CST
Northwest Biotherapeutics (NASDAQ: NWBO) ("NW Bio"
NWBO: 5.58 (+0.04)
NWBO: DCVax-Direct Validation And Updated DCVax-L Ph III Modeling
Steven Giardino - at Seeking Alpha - Thu Nov 06, 3:15PM CST
NWBO: 5.58 (+0.04), CLDX: 17.08 (-0.18)
The most undervalued, yet comprehensive cancer immunotherapy in development?
ACCESSWIRE - Mon Nov 03, 7:03AM CST
Los Angeles, CA / ACCESSWIRE / November 3, 2014 / The National Cancer Institute (NCI) spends upwards of $4.9 billion each year on cancer research.
INO: 9.11 (-0.09), NWBO: 5.58 (+0.04), DNDN: 0.13 (-0.02), GALE: 1.49 (-0.02)
The Time Is Now For Northwest Biotherapeutics
Steven Giardino - Seeking Alpha - Wed Oct 29, 2:16PM CDT
Northwest Biotherapeutics (NASDAQ: NWBO ) has achieved a number of significant milestones over the past year while seeing its share price rise consistently on an upward trend, until somewhat recently. It may seem at first that the Company either...
NWBO: 5.58 (+0.04), PCYC: 121.84 (+1.15), JAZZ: 165.33 (+1.83), ICPT: 151.49 (+5.85), AAPL: 112.01 (-0.53)
SHAREHOLDER ALERT: The Law Firm of Levi & Korsinsky, LLP Launches an Investigation into Possible Violations of Federal Securities Laws by the Board of Directors of Northwest Biotherapeutics, Inc.
PR Newswire - Tue Oct 28, 1:41PM CDT
Levi & Korsinsky, LLP is investigating Northwest Biotherapeutics, Inc. ("Northwest Bio" or the "Company"
NWBO: 5.58 (+0.04)
Washington Post’s Pearlstein Didn't Intend to Disparage TheStreet’s Integrity
at The Street - Tue Oct 28, 1:32PM CDT
Steven Pearlstein, columnist for the Washington Post, says he never meant to disparage TheStreet's editorial standards in his Sept. 27 column examining TheStreet's Northwest Bio coverage.
TST: 2.46 (+0.03), NWBO: 5.58 (+0.04)
NORTHWEST BIOTHERAPEUTICS INC. ALERT -- Andrews & Springer LLC is Investigating Northwest Biotherapeutics Inc. for Potential Securities Fraud
GlobeNewswire - Mon Oct 20, 7:01AM CDT
Andrews & Springer LLC, a boutique securities class action law firm focused on representing shareholders nationwide, is investigating potential securities fraud claims against Northwest Biotherapeutics Inc. ("NWBO" or the "Company"
NWBO: 5.58 (+0.04)